Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
|
|
- Bartholomew Edwards
- 5 years ago
- Views:
Transcription
1 Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist participants should be able to: Describe the major differences and controversies between current and previous guidelines Discuss the rationale for updated treatment strategies as compared to previous treatment goals Differentiate high and moderate- intensity statin therapy and indications for each Identify the 4 statin benefit groups as described in the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines At the end of this presentation, technician participants should be able to: Discuss atherosclerotic cardiovascular disease (ASCVD) and its associated risks for complications and death. Identify patient populations at risk for ASCVD Describe the medications used to reduce the risk of ASCVD. Are you applying the new ACC/AHA Lipid guidelines in your practice? A. Yes B. No C. A little bit, but I m still not completely comfortable. Key Differences No more LDL goals and non-hdl goals Statin benefit groups ASCVD 10-year risk estimation Safety recommendations References: Neil J. Stone, Jennifer Robinson, Alice H. Lichtenstein, et al ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. published online November 12, ASCVD Risk Calculator 1
2 What is ASCVD? Atherosclerotic Cardiovascular Disease Coronary Artery Disease (CAD) or Coronary Heart Disease (CHD) History of cardiovascular events including: Myocardial infarction (MI) Angina Stroke or Transient ischemic attack (TIA) Acute Coronary Syndrome (ACS) Coronary vascularization Peripheral Arterial Disease (PAD) ASCVD Facts Leading cause of death and medical costs in the United States 1 in 3 Americans die of heart disease and stroke ASCVD can be prevented by: Healthy lifestyle: Regular physical activity, healthy diet, avoiding smoking, maintaining healthy weight Treatment of cholesterol and blood pressure (Adult Treatment Panel)- ATP III Guidelines 2001 Low density lipoprotein (LDL) goals based on CHD risk Framingham scoring tool to help determine 10 year CHD risk LDL goal <100 mg/dl for secondary prevention OR CHD risk equivalents (ex. Diabetes mellitus (DM) LDL goal <130 mg/dl for patients with > 2 following risk factors: HTN, age (male >45, female >55), active smoking, low HDL, premature family history (FH) of heart disease) LDL goal <160 mg/dl for patients with 0-1 of the above risk factors) Provided recommendations for patients with elevated triglycerides (TG) and low high-density cholesterol (HDL) JAMA 2001;285: ACC/AHA Guidelines (ATP-IV) American College of Cardiology (ACC) and American Heart Association (AHA) in collaboration with National Heart, Lung and Blood Institute (NHLBI) Focus on ASCVD Risk Reduction No more LDL goals ASCVD calculator Use of four risk groups to help guide treatment Emphasis on medications proven to lower ASCVD events Fixed statin doses (moderate, high intensity) Decreased focus on non-statins Circulation 2013 ACC/AHA Guidelines on Cholesterol (e-publication Similarities Both guidelines seek to lower the risk of cardiovascular events Both sets of guidelines emphasize a healthy lifestyle Avoidance of smoking Maintain healthy weight Physical activity Healthy Diet Dietary recommendations The 2013 ACC/AHA Lifestyle Management Guideline Dietary recommendations*: Low saturated fat Low trans fat Low sodium Eat more: Vegetables, fruits, whole grains, low fat dairy, poultry, fish, nuts, non tropical vegetable oils Patients should limit: sweets, sugar-sweetened beverages, red meats *Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA, et al ACC/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (PMID: ). 2
3 Update on the Lipid Guidelines There is no randomized controlled trial (RCT) evidence to support LDL or non-hdl treatment targets. The RCTs identified in the panel s review of the evidence indicated a consistent reduction in ASCVD events with statin therapy in primary AND secondary prevention. Exception: NYHA Class II-IV heart failure and patients receiving hemodialysis Four groups that benefit from statin therapy Four Major Statin Benefit Groups Patients ( 21 years old) WITH clinical ASCVD Patients ( 21 years old) with LDL of 190 mg/dl Patients with Diabetes age with LDL mg/dl No clinical ASCVD or DM- age with LDL mg/dl and 10 year ASCVD risk >7.5 ASCVD 10-year risk calculator Provides 10 year ASCVD risk estimate for patients aged Tk Takes into account: Age, gender, Smoking status, HTN, BP, TC, HDL, DM, stroke, and race Also helpful to use apps if using a smart phone Patient Case #1 Dexter Morgan is a 40 year old Caucasian male who visits your clinic. PMH: + smoking, HTN (hypertension). Today, his BP is 148/92. Current medications: Lisinopril 10 mg daily Labs: TC 238, TG 298, HDL 39, LDL 142, A1c 8.9%, SCr 1.1. What is Mr. Morgan s ASCVD score? A. 2.5% B. 5.7% C. 11.1% D. 20% 3
4 Mr. Morgan should receive a statin. A. True B. False Intensity of statin therapy in primary and secondary prevention of ASCVD High Intensity Statin Therapy Daily dose lowers LDL C, on average, by approximately 50% Atorvastatin (40) 80 mg Rosuvastatin 20 (40) mg Moderate Intensity Statin Therapy Daily dose lowers LDL C, on average, by approximately 30% to <50% Atorvastatin mg Rosuvastatin 5 10 mg Simvastatin mg Pravastatin mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 2 4 mg Low Intensity Statin Therapy Daily dose lowers LDL C, on average, by <30% Simvastatin 10 mg Pravastatin mg Lovastatin 20 mg Fluvastatin mg Pitavastatin 1 mg Circulation 2013 ACC/AHA Guidelines on Cholesterol (e-publication). Statin Groups/Recommendations Patients ( 21 y/o) with clinical ASCVD: High Intensity Statin Patients ( 21 y/o) with LDL of 190 mg/dl: High Intensity Statin Patients with Diabetes age with LDL mg/dl 10 year ASCVD risk < 7.5%: Moderate Intensity Statin 10 year ASCVD risk 7.5%: High Intensity Statin No clinical ASCVD or DM- age with LDL mg/dl and 10 year ASCVD risk >7.5 Moderate-High Intensity Statin Circulation 2013 ACC/AHA Guidelines on Cholesterol (e-publication). Fi Case #2: Ms. Wolowitz Ms. Wolowitz is a 53 y/o Caucasian female with a PMH of Type 2 DM, obesity, and HTN. She does not smoke. She currently does not have prescription coverage. She takes losartan 25 mg daily, y,pravastatin 20 mg daily, Aspirin 81 mg daily, metformin 1000 mg twice daily BP today: 132/90 Lipid panel results: TC 198, TG 96, HDL 38, LDL 62 What is Mrs. Wolowitz s 10- year ASCVD score? A. 2.3% B. 5.0% C. 6.5% D. 9.7% 4
5 Your recommendation for Ms. Wolowitz? A. Continue present management B. Increase pravastatin to 40 mg daily C. Switch to rosuvastatin 10 mg daily D. Add ezetimibe 10 mg daily Non-Statin Therapy The panel states that non-statin therapies do not offer benefit at reducing ASCVD risk. (Examples: ezetimibe, fish oil, niacin, fibrates) Consider non-statin therapy if: Patient does not respond as expected to statin therapy Patient is unable to tolerate appropriate statin intensity Statin intolerance Safety of Statin Therapy Myalgias (0.5-5%) Rhabdomyolysis (0.002%) Contraindicated in pregnancy and in patients with active liver disease. Recent addition to statin labeling in 2012 Reversible memory loss, confusion Increased blood sugar and A1c- new onset DM The FDA states that the BENEFITS of statins outweighs the above risks. Laboratory Monitoring Baseline tests: A1c, LFTs, thyroid to rule out secondary causes of dyslipidemia Fasting Lipid panel Within 4-12 weeks after initiation or dose adjustment of drug therapy and every 3-12 months thereafter LFTs- at baseline and as clinically indicated thereafter The FDA revised labels in Feb 2012 to remove the need for periodic LFT monitoring Laboratory monitoring CK (Creatine Kinase) At baseline in patients at risk for myopathy. Repeat if symptoms of muscle pain How low is too low for LDL? The guidelines state that patients with LDL <40 mg/dl on two consecutive occasions should have statin dose reduced. Limited evidence on this topic Many statin drug-drug interactions Statins are metabolized by CYP450 system Atorvastatin, lovastatin, and simvastatin 3A4 Strong 3A4 inhibitors increased statin ADRs Erythromycin, Clarithromycin, Protease inhibitors, Azole antifungals, verapamil, diltiazem, amiodarone FDA Simvastatin dosing limitations Decreased statin effectiveness with inducers (rifampin, carbamazepine, phenytoin) fluvastatin 2C9 rosuvastatin 2C9/2C19 pravastatin and pitavastatin minimal hepatic metabolism Avoid gemfibrozil in combination with statins Separate administration of colesevelam, cholestyramine by 4 hours 5
6 Other clinical recommendations Consider moderate-intensity doses for patients who would qualify for high-intensity but have certain characteristics that predispose them to side effects > 75 years old Multiple or serious comorbidities, including impaired renal or hepatic impairment History of previous statin intolerance or muscle disorders Unexplained ALT elevations > 3x ULN Concomitant drugs that affect statin metabolism Use the maximally tolerated intensity of statin for patients unable to tolerate the recommended intensity Case #3 Carl Fredricksen is a 73 year old male with a history of CAD (CABG in 2010), Type 2 DM, and HTN He presents to your pharmacy with a prescription for atorvastatin 40 mg daily. He tells you he is afraid to take statins because he one time got muscle pain while on simvastatin. He asks you about your opinion. Ann Intern Med. 2014;160: Should Mr. Fredricksen start taking the atorvastatin? A. Yes, because he has ASCVD B. Yes, because of his ASCVD 10-year risk ik C. No, because of his history of myalgias on statin therapy D. No, because he warrants moderate intensity statin therapy Managing statin complaints Mr. Fredricksen returns to the pharmacy 4 weeks after starting his prescription for atorvastatin. He is complaining of muscle pain- mainly in the upper thigh. Next steps? Have a discussion regarding the patient s symptoms, history, and timeline Refer this patient to his physician for further evaluation Managing myalgias D/c statin temporarily Consider checking CK level- especially if severe pain R l h bl Rule out other possible causes Renal or hepatic impairment, musculoskeletal/ rheumatologic conditions, vitamin D deficiency Can re-challenge with either the same statin, or an alternative statin at same or lower intensity 6
7 Some evidence gaps and limitations of ATP-IV Expert panel was not able to find evidence for statin benefit for Class II-IV heart failure or receiving hemodialysis 10 year ASCVD Risk estimation limitations: Calculator only for age May overestimate risk in some patients Risk estimation requires TC range of mg/dl Does not take into account family history Still unclear evidence regarding combination therapy Risk of new-onset diabetes with statin therapy? LDL <100 as a quality measure- will this change? Are the ATP4 being embraced? Pros Somewhat of a simplified approach More evidence-based approach Less monitoring? Clear guidance for medication recommendations Cons Many clinicians are still comfortable with LDL goals Patient concerns: Why do I need medicinemy cholesterol has always been low? When they increased my statin- my muscles hurt Estimated 10-year ASCVD risk calculator has not been evaluated Controversy in the Media Message from AHA CEO regarding myths surrounding ATP-IV Lifestyle choices no longer matter False! A healthy lifestyle remains the foundation of preventing ASCVD These guidelines may lead to unnecessary prescribing of statins False! Goal is to have a more individualized approach Statins cause more harm than good False! Statins are considered safe medications overall. Benefits outweigh the risks in most patients These guidelines were influenced by the pharmaceutical industry. False! The ACC/AHA expert panel had a strict disclosure policy. Also, many statins are available as low-cost generics. Summary The ATP-IV guidelines present an evidence-based approach to lipid management to prevent ASCVD Remember the 4 statin risk groups A healthy lifestyle is the foundation for lowering the risk of ASCVD Clinical judgment is warranted in many scenarios There are still many questions remaining Any Questions? 7
8 What s the Skinny on the Lipid Guidelines? Pharmacy Technician Self Assessment Questions 1. Which of the following is considered clinical ASCVD (atherosclerotic cardiovascular disease)? a. High Blood pressure b. High Cholesterol c. Chronic kidney disease d. Previous stroke 2. Which of the following is the brand name for rosuvastatin? a. Lipitor b. Crestor c. Zetia d. Zocor 3. Which of the following medications has been associated with significantly reducing the risk of ASCVD? a. Ezetimibe b. Omega 3 fish oil caps c. Vitamin E d. Atorvastatin 4. According to the new guidelines, which of the following patients would likely have the greatest benefit from high intensity statin therapy? a. A 45 year old patient with an ASCVD score of 3% b. A 90 year old patient with diabetes. c. A 60 year old male with a recent heart attack. d. A 25 year old patient that smokes 1 pack of cigarettes per day. 5. Which of the following statins is NOT available as a generic at this time? a. Rosuvastatin b. Atorvastatin c. Simvastatin d. Pravastatin Key: 1. D; 2. B; 3. D; 4. C; 5. A
Acute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More information2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2
2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2 GOALS ACC/AHA as publisher of guidelines Determining which patients are appropriate for statin therapy The treatment
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationCPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction
CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationSpeaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014
Speaker Disclosure Erica Pearce, Pharm.D. declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More information2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationApplying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients
Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients Joe Anderson, PharmD, PhC, BCPS James Nawarskas, PharmD, PhC, BCPS Gretchen Ray, PharmD, PhC, BCACP University of
More informationHyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationTHE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL
THE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL Anne Carol Goldberg, MD, FACP, FAHA, FNLA Associate Professor of Medicine Washington University School of Medicine National Lipid Association
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPREV E E V N E TI T O I N
PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE SHANE JOHNSON,, PHARM. D. OBJECTIVES 1. Define atherosclerotic cardiovascular disease(s) and describe the disease progression. 2. Identify three independent
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationUnderstanding US Lipid Guidelines-2013:
Presentation to NLA Symposium: May 3 2014 Understanding US Lipid Guidelines-2013: Neil J. Stone MD, MACP, FACC Bonow Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Il
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationToday s Recommendations
Today s Recommendations 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk (45 pages) 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults (14 pages)
More informationUpdate on the Treatment of Hyperlipidemia
Update on the Treatment of Hyperlipidemia Wafaa Abou-Zeineddine, PharmD Medstar Washington Hospital Center Washington Metropolitan Society of Health Systems Pharmacists May 30, 2015 Please MUTE phones
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES
DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-249-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National
More informationDyslipidemia: What s New In The Guidelines?
1 Dyslipidemia: What s New In The Guidelines? Rhonda Cooper-DeHoff, Pharm D, MS Associate Professor Colleges of Pharmacy and Medicine University of Florida Disclosures 2 No actual or perceived conflicts
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationHypertension and Hyperlipidemia. University of Illinois at Chicago College of Nursing
Hypertension and Hyperlipidemia University of Illinois at Chicago College of Nursing 1 Learning Objectives 1. Provide a basic level of knowledge regarding hypertension and hyperlipidemia and care coordinators/
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLecture 36 Dyslipidemia Therapeutics Barry LIPIDS:
LIPIDS: PATHOPHYSIOLOGY: TC or LDL-C = CVD HDL-C = CVD Association between TG and CVD not established o HyperTG associated with pancreatitis o Reducing TG w/ drug therapy doesn t CVD TYPES OF DYSLIPIDEMIA:
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationCARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK?
1 CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK? Perry J Weinstock, MD, F.A.C.C. Head, Division of Cardiovascular Disease Director of Clinical Cardiology Cooper
More informationObjec ves To discuss the process of formulation of guidelines and how this may differ among professional societies 5/14/15
Kellie McLain, NP- C, CLS Medical University of South Carolina Cardiology Division Seinsheimer Cardiovascular Prevention and Lipid Program May 29 th, 2015 Objecves To discuss the process of formulation
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More information